Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis

Blood (2017) 130 (Supplement 1): 1743.

https://doi.org/10.1182/blood.V130.Suppl_1.1743.1743

Published: 2017

Journal Articles

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

Blood (2015) 126 (23): 2745.

https://doi.org/10.1182/blood.V126.23.2745.2745

Published: 2015

Journal Articles

A Somatic Variant in MYD88 (L265P) Revealed by Whole Genome Sequencing Differentiates Lymphoplasmacytic Lymphoma From Marginal Zone Lymphomas

Lian Xu, Aliyah R. Sohani, MD, Luca Arcaini, MD, Zachary Hunter, Guang Yang, PhD, Yangsheng Zhou, MD, Xia Liu, MD, Yang Cao, MD, Robert Manning, Christopher J Patterson, Leukothea Ioakimidis, Christina Tripsas, Geraldine S. Pinkus, MD, Nancy Lee Harris, MD, Scott J. Rodig, MD, PhD, Steven Treon, MD, PhD

Blood (2011) 118 (21): 261.

https://doi.org/10.1182/blood.V118.21.261.261

Published: 2011

Journal Articles

Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Irene M. Ghobrial, MD, Erica N Boswell, BS, Ranjit Banwait, MA, Tiffany Poon, BS, Amanda Donovan, BS, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Meghan Bagshaw, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Steven Treon, MD, PhD

Blood (2011) 118 (21): 2705.

https://doi.org/10.1182/blood.V118.21.2705.2705

Published: 2011

Journal Articles

Incidence of Peripheral Neuropathy in Waldenström Macroglobulinemia Patients At Diagnosis,

Claudia E. Paba-Prada, MD, Ranjit Banwait, MA, Steven Treon, MD, PhD, Irene M. Ghobrial, MD

Blood (2011) 118 (21): 3692.

https://doi.org/10.1182/blood.V118.21.3692.3692

Published: 2011

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

Irene M. Ghobrial, M.D., Fangxin Hong, PhD, Swaminathan Padmanabhan, MD, Ashraf Z. Badros, MD, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, NP, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D., Steven Treon, MD, PhD, Edie Weller, PhD, Jeffrey Matous

Blood (2009) 114 (22): 2727.

https://doi.org/10.1182/blood.V114.22.2727.2727

Published: 2009

Journal Articles

Involvement of Ets Factor Spi-B, E Protein E2-2, and Id2 in Waldenström's Macroglobulinemia.

Yangsheng Zhou, MD, PhD, Xia Liu, Lian Xu, Zachary Hunter, Jenny Sun, MD, Guang Yang, PhD, Bryan Ciccarelli, Christopher J Patterson, Lee A. Garrett-Sinha, PhD, Steven Treon, MD, PhD

Blood (2009) 114 (22): 2946.

https://doi.org/10.1182/blood.V114.22.2946.2946

Published: 2009

Journal Articles

Polymorphisms of FcγRIIA, FcγRIIB, and FcγRIIIA and Therapeutic Response to Rituximab Combination Therapy in Patients with Waldenstrom's Macroglobulinemia.

Guang Yang, PhD, Christina Hanzis, Ping Gong, Sigitas Verselis, PhD, Edward A. Fox, PhD, Lian Xu, Bryan Ciccarelli, Yangsheng Zhou, MD, PhD, Zachary Hunter, Jenny Sun, MD, Xia Liu, Hsiuyi Tseng, Yang Cao, Robert Manning, Megan Lewicki, Thea Ioakimidis, MS, Patricia Sheehy, NP, Christopher J Patterson, Steven Treon, MD, PhD

Blood (2009) 114 (22): 2949.

https://doi.org/10.1182/blood.V114.22.2949.2949

Published: 2009

Journal Articles

Micro-RNA Expression Profiling Reveals Distinct Correlates to Disease Pathogenesis, and Identifies Novel Pathways Involved in Tumor Cell Senescence and IL-12A Signaling.

Zachary Hunter, Jenny Sun, MD, Sophia Adamia, Yang Cao, Hsiuyi Tseng, Megan Lewicki, Lian Xu, Guang Yang, PhD, Yangsheng Zhou, MD, PhD, Xia Liu, Ping Gong, Christina Hanzis, Thea Ioakimidis, MS, Bryan Ciccarelli, Robert Manning, Patricia Sheehy, NP, Christopher J Patterson, Christopher Andry, BSc, MPhil, PhD, Steven Treon, MD, PhD

Blood (2009) 114 (22): 2950.

https://doi.org/10.1182/blood.V114.22.2950.2950

Published: 2009

Journal Articles

Patients with Waldenstrom's Macroglobulinemia Are Often Hypoferremic That Is Refractory to Oral Iron Repletion and Responsive to Parental Iron Infusions, and Demonstrate Elevated Levels of Hepcidin.

Bryan Ciccarelli, Christopher J Patterson, Zachary Hunter, Christina Hanzis, Thea Ioakimidis, MS, Robert Manning, Guang Yang, PhD, Ping Gong, Lian Xu, Yangsheng Zhou, MD, PhD, Jenny Sun, MD, Xia Liu, Hsiuyi Tseng, Yang Cao, Patricia Sheehy, NP, Steven Treon, MD, PhD

Blood (2009) 114 (22): 2952.

https://doi.org/10.1182/blood.V114.22.2952.2952

Published: 2009

Journal Articles

Aberrant DNA Methylation and Transcriptional Silencing of DLC-1 in Waldenstrom's Macroglobulinemia.

Lian Xu, Bryan Ciccarelli, Evdoxia Hatjiharissi, MD, Guang Yang, PhD, Yangsheng Zhou, MD, PhD, Zachary Hunter, Jenny Sun, MD, Ping Gong, Xia Liu, Hsiuyi Tseng, Thea Ioakimidis, MS, Robert Manning, Christina Hanzis, Yang Cao, Megan Lewicki, Christopher J Patterson, Steven Treon, MD, PhD

Blood (2009) 114 (22): 2954.

https://doi.org/10.1182/blood.V114.22.2954.2954

Published: 2009

Journal Articles

Metalloproteinase Inhibitors Inhibit the Release of Soluble CD27 by Waldenström's Macroglobulinemia Cells.

Yangsheng Zhou, MD, PhD, Xia Liu, Ping Gong, Lian Xu, Bryan Ciccarelli, Guang Yang, PhD, Christopher J Patterson, Steven Treon, MD, PhD

Blood (2009) 114 (22): 3942.

https://doi.org/10.1182/blood.V114.22.3942.3942

Published: 2009

Journal Articles

Involvement of Fatty Acid Synthase in Azacytidine-Induced Cytotoxicity in Waldenstrom's Macroglobulinemia.

Lian Xu, Christopher J Patterson, Jenny Sun, MD, Guang Yang, PhD, Yangsheng Zhou, MD, PhD, Zachary Hunter, Evdoxia Hatjiharissi, MD, Bryan Ciccarelli, Ping Gong, Xia Liu, Hsiuyi Tseng, Thea Ioakimidis, MS, Robert Manning, Christina Hanzis, Yang Cao, Megan Lewicki, Steven Treon, MD, PhD

Blood (2009) 114 (22): 3731.

https://doi.org/10.1182/blood.V114.22.3731.3731

Published: 2009

Journal Articles

The Inhibitory Receptor FcgRIIB Is Overexpressed, and Its Ligation by Anti- FcgRIIB Antibodies Suppresses IgM Production and Induces Apoptosis in Waldenstrom's Macroglobulinemia.

Guang Yang, PhD, Ping Gong, Lian Xu, Zachary Hunter, Jenny Sun, MD, Bryan Ciccarelli, Yangsheng Zhou, MD, PhD, Xia Liu, Hsiuyi Tseng, Yang Cao, Robert Manning, Megan Lewicki, Christina Hanzis, Thea Ioakimidis, MS, Patricia Sheehy, NP, Christopher J Patterson, Steven Treon, MD, PhD

Blood (2009) 114 (22): 3736.

https://doi.org/10.1182/blood.V114.22.3736.3736

Published: 2009

Journal Articles

Vorinostat Induced Cellular Stress Disrupts the Balance Between p38 MAPK and Erk Pathways Leading to Apoptosis in WM Cells.

Jenny Sun, MD, Hsiuyi Tseng, Lian Xu, Zachary Hunter, Bryan Ciccarelli, Mariateresa Fulciniti, Guang Yang, PhD, Ping Gong, Yangsheng Zhou, MD, PhD, Xia Liu, Nikhil C. Munshi, Christopher J Patterson, Steven Treon, MD, PhD

Blood (2009) 114 (22): 3740.

https://doi.org/10.1182/blood.V114.22.3740.3740

Published: 2009

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.

Irene M. Ghobrial, M.D., Swaminathan Padmanabhan, Ashraf Z. Badros, MD, Renee Leduc, Meghan Rourke, Stacey Chuma, Janet Kunsman, NP, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D., Steven Treon, MD, PhD, Jeffrey Matous

Blood (2009) 114 (22): 3752.

https://doi.org/10.1182/blood.V114.22.3752.3752

Published: 2009

Journal Articles

Gene Expression Profiling Distinguishes Waldenstrom's Macroglobulinemia Patients Presenting with Familial Disease, Advanced IPSS Prognostic Score, and Previous Treatment with Rituximab.

Zachary Hunter, Evdoxia Hatjiharissi, MD, Jenny Sun, MD, Yang Cao, Hsiuyi Tseng, Megan Lewicki, Lian Xu, Guang Yang, PhD, Yangsheng Zhou, MD, PhD, Xia Liu, Ping Gong, Christina Hanzis, Thea Ioakimidis, MS, Christopher J Patterson, Patricia Sheehy, NP, Bart Barlogie, MD, PhD, John D Shaughnessy, Jr, PhD, Steven Treon, MD, PhD

Blood (2009) 114 (22): 3930.

https://doi.org/10.1182/blood.V114.22.3930.3930

Published: 2009

Journal Articles

The IgM Flare Following Rituximab and IVIG Administration in Waldenstrom's Macroglobulinemia Is Related to IL-6 Production by Bystander Immune Cells, Possibly through Stimulation of the Fcgriia Receptor.

Guang Yang, PhD, Ping Gong, Thea Ioakimidis, MS, Lian Xu, Zachary Hunter, Jenny Sun, MD, Bryan Ciccarelli, Yangsheng Zhou, MD, PhD, Xia Liu, Hsiuyi Tseng, Yang Cao, Robert Manning, Megan Lewicki, Christina Hanzis, Patricia Sheehy, NP, Christopher J Patterson, Steven Treon, MD, PhD

Blood (2009) 114 (22): 761.

https://doi.org/10.1182/blood.V114.22.761.761

Published: 2009

Journal Articles

Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom's Macroglobulinemia.

Blood (2009) 114 (22): 4785.

https://doi.org/10.1182/blood.V114.22.4785.4785

Published: 2009

Journal Articles

Cholesterol Regulation and Statin Therapy in Patients with Waldenstrom's Macroglobulinemia.

Thea Ioakimidis, MS, Christopher J Patterson, Zachary Hunter, Jacob Soumerai, Robert Manning, Diane L. Warren, Irene Ghobrial, M.D., Patricia Sheehy, NP, Steven Treon, MD, PhD

Blood (2009) 114 (22): 4789.

https://doi.org/10.1182/blood.V114.22.4789.4789

Published: 2009

NARROW

Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

A Somatic Variant in MYD88 (L265P) Revealed by Whole Genome Sequencing Differentiates Lymphoplasmacytic Lymphoma From Marginal Zone Lymphomas

Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Incidence of Peripheral Neuropathy in Waldenström Macroglobulinemia Patients At Diagnosis,

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

Involvement of Ets Factor Spi-B, E Protein E2-2, and Id2 in Waldenström's Macroglobulinemia.

Polymorphisms of FcγRIIA, FcγRIIB, and FcγRIIIA and Therapeutic Response to Rituximab Combination Therapy in Patients with Waldenstrom's Macroglobulinemia.

Micro-RNA Expression Profiling Reveals Distinct Correlates to Disease Pathogenesis, and Identifies Novel Pathways Involved in Tumor Cell Senescence and IL-12A Signaling.

Patients with Waldenstrom's Macroglobulinemia Are Often Hypoferremic That Is Refractory to Oral Iron Repletion and Responsive to Parental Iron Infusions, and Demonstrate Elevated Levels of Hepcidin.

Aberrant DNA Methylation and Transcriptional Silencing of DLC-1 in Waldenstrom's Macroglobulinemia.

Metalloproteinase Inhibitors Inhibit the Release of Soluble CD27 by Waldenström's Macroglobulinemia Cells.

Involvement of Fatty Acid Synthase in Azacytidine-Induced Cytotoxicity in Waldenstrom's Macroglobulinemia.

The Inhibitory Receptor FcgRIIB Is Overexpressed, and Its Ligation by Anti- FcgRIIB Antibodies Suppresses IgM Production and Induces Apoptosis in Waldenstrom's Macroglobulinemia.

Vorinostat Induced Cellular Stress Disrupts the Balance Between p38 MAPK and Erk Pathways Leading to Apoptosis in WM Cells.

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.

Gene Expression Profiling Distinguishes Waldenstrom's Macroglobulinemia Patients Presenting with Familial Disease, Advanced IPSS Prognostic Score, and Previous Treatment with Rituximab.

The IgM Flare Following Rituximab and IVIG Administration in Waldenstrom's Macroglobulinemia Is Related to IL-6 Production by Bystander Immune Cells, Possibly through Stimulation of the Fcgriia Receptor.

Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom's Macroglobulinemia.

Cholesterol Regulation and Statin Therapy in Patients with Waldenstrom's Macroglobulinemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only